and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed ...

MURA will lead this week’s cliff unlocks when ... Following suit, Dogecoin (DOGE) plans to release 97.01 million tokens worth $25.90 million, affecting 0.07% of its total supply.

Raymond James downgraded Mural Oncology (MURA) to Outperform from Strong Buy with a price target of $6, down from $18, after the company ...

In a report released today, Laura Prendergast from Raymond James downgraded Mural Oncology Plc (MURA – Research Report) to a Buy, with a price ...

Find the latest Mural Oncology plc MURA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.